DVDMS-PDT在晚期食管癌治疗中的生存获益分析

In this study, the overall survival (OS) was similar between the DVDMS-PDT and TPC groups. However, from the shape of the survival curves, it can be observed that the OS curve for the TPC group showed a trend of slowing decline in the later stages, which may be related to the fact that patients in the TPC group were allowed to cross over to receive DVDMS-PDT treatment subsequently. After correction using the RPSFTM method, it was observed that DVDMS-PDT could significantly reduce the risk of death. Additionally, the median OS (mOS) of patients treated with DVDMS-PDT in this study was slightly higher compared to previous palliative treatments [13], and was similar to the mOS reported in previous explorations of systemic therapies (such as immunotherapy and targeted therapy) in second- and third-line settings for advanced esophageal cancer [14-16]. It is important to note that all patients included in this study had progressed after prior systemic therapy, experienced dysphagia, and had limited treatment options. Furthermore, patients with a high tumor burden (stage IV and baseline presence of more than two metastatic sites) who received DVDMS-PDT treatment showed significant survival benefits, possibly due to the poor prognosis associated with the treatment of physician's choice in high tumor burden patients. This suggests that for patients with a high tumor burden, poor response to conventional treatments, and limited treatment options, DVDMS-PDT may be an effective therapeutic option. Although there was no head-to-head comparison, achieving an mOS similar to other curative-intent systemic therapies indicates the potential survival benefit of DVDMS-PDT, both in terms of its anti-tumor effects and symptom improvement.